DOSE RESPONSE RELATIONSHIP OF HYDROXYCHLOROQUINE SULPHATE IN THE TREATMENT OF RHEUMATOID ARTHRITIS: A RANDOMISED CONTROL STUDY

Background: RA is an autoimmune disease triggered by faulty immune system and affects various joints of body including wrist and finger. Nowadays slow acting or DMARDs (Disease modifying anti-rheumatoid drugs) are mainstay of treatment in RA. HCQs belong to this group. They are slow acting so they t...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:International journal of pharmaceutical sciences and research 2017-02, Vol.8 (2), p.856-856
Hauptverfasser: Modi, Jayprakash V, Patel, Kaushal R, Patel, Zulfikar M, Patel, Harshil R, Dhanani, Shreekant S, Shah, Bhavya H
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 856
container_issue 2
container_start_page 856
container_title International journal of pharmaceutical sciences and research
container_volume 8
creator Modi, Jayprakash V
Patel, Kaushal R
Patel, Zulfikar M
Patel, Harshil R
Dhanani, Shreekant S
Shah, Bhavya H
description Background: RA is an autoimmune disease triggered by faulty immune system and affects various joints of body including wrist and finger. Nowadays slow acting or DMARDs (Disease modifying anti-rheumatoid drugs) are mainstay of treatment in RA. HCQs belong to this group. They are slow acting so they take weeks to months to become effective. HCQ is less effective when compared to gold or penicillamine but its tolerance is better than other DMARDs. Objective: 1. To observe a dose-response relationship for hydroxychloroquine (HCQ), in terms of the proportion of patients achieving the Paulus 20% criteria for improvement in patients with rheumatoid arthritis (RA) receiving a 24 week loading regimen of 400, 800, or 1,200 mg HCQ daily. 2. To investigate possible relationships between increased dosage of HCQ and measures of efficacy and toxicity. Methods: 422 Patients with RA began a 24-week study comparing 3 different doses of HCQ at 400, 800, or 1,200 mg/day, followed by 18 weeks of open-label HCQ treatment at 400 mg/day. Patients were evaluated at 0, 6 and 18 week to measure the efficacy and adverse reaction of the drug. Results: There was a positive correlation between the Paulus 20% improvement criteria response and increased dose of HCQs during weeks 1-6 (P < 0.001). Adverse gastrointestinal events were associated with higher HCQ levels (P
doi_str_mv 10.13040/IJPSR.0975-8232.8(2).856-58
format Article
fullrecord <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_miscellaneous_1877834457</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1877834457</sourcerecordid><originalsourceid>FETCH-LOGICAL-p118t-d294e0844ad627fc6d6187d23b012b7040cdc42e905ce17a5648c38b549e8dbb3</originalsourceid><addsrcrecordid>eNo9UMtOwzAAi5CQmMb-IQcO49CS5tGm3KI2kKCuKWkqsdPURyaBBht0u_LtlIfwxZZlWZYBuIpQGBFE0Y1-qGobojRhAccEh3yJr0PO4oDxMzD79y_AYhxf0IQYRxEnM_CZm1pCK-vKlD-iEE5PUukKmjuo1rk1T-tMFcaax0aXEtZNUSnhJNQldEpCZ6VwK1m677xVslkJZ3QOhXXKaqfrWyigFWVuVrqWOcxM6awpYO2afH0JzrftbvSLP56D5k66TAWFudeZKILDNPMYDDilHnFK2yHGybaPhzjiyYBJhyLcJdMD_dBT7FPEeh8lLYsp7wnvGE09H7qOzMHyt_fwsX8_-fG4eX0ee7_btW9-fxo3U1vCCaUsIV9lfVnS</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1877834457</pqid></control><display><type>article</type><title>DOSE RESPONSE RELATIONSHIP OF HYDROXYCHLOROQUINE SULPHATE IN THE TREATMENT OF RHEUMATOID ARTHRITIS: A RANDOMISED CONTROL STUDY</title><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Modi, Jayprakash V ; Patel, Kaushal R ; Patel, Zulfikar M ; Patel, Harshil R ; Dhanani, Shreekant S ; Shah, Bhavya H</creator><creatorcontrib>Modi, Jayprakash V ; Patel, Kaushal R ; Patel, Zulfikar M ; Patel, Harshil R ; Dhanani, Shreekant S ; Shah, Bhavya H</creatorcontrib><description>Background: RA is an autoimmune disease triggered by faulty immune system and affects various joints of body including wrist and finger. Nowadays slow acting or DMARDs (Disease modifying anti-rheumatoid drugs) are mainstay of treatment in RA. HCQs belong to this group. They are slow acting so they take weeks to months to become effective. HCQ is less effective when compared to gold or penicillamine but its tolerance is better than other DMARDs. Objective: 1. To observe a dose-response relationship for hydroxychloroquine (HCQ), in terms of the proportion of patients achieving the Paulus 20% criteria for improvement in patients with rheumatoid arthritis (RA) receiving a 24 week loading regimen of 400, 800, or 1,200 mg HCQ daily. 2. To investigate possible relationships between increased dosage of HCQ and measures of efficacy and toxicity. Methods: 422 Patients with RA began a 24-week study comparing 3 different doses of HCQ at 400, 800, or 1,200 mg/day, followed by 18 weeks of open-label HCQ treatment at 400 mg/day. Patients were evaluated at 0, 6 and 18 week to measure the efficacy and adverse reaction of the drug. Results: There was a positive correlation between the Paulus 20% improvement criteria response and increased dose of HCQs during weeks 1-6 (P &lt; 0.001). Adverse gastrointestinal events were associated with higher HCQ levels (P &lt;=0.001) during 0-3 weeks. Conclusion: There is a weak, but predictable, relationship between increase HCQs dosage and efficacy of treatment with HCQ.</description><identifier>EISSN: 0975-8232</identifier><identifier>DOI: 10.13040/IJPSR.0975-8232.8(2).856-58</identifier><language>eng</language><ispartof>International journal of pharmaceutical sciences and research, 2017-02, Vol.8 (2), p.856-856</ispartof><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,778,782,27907,27908</link.rule.ids></links><search><creatorcontrib>Modi, Jayprakash V</creatorcontrib><creatorcontrib>Patel, Kaushal R</creatorcontrib><creatorcontrib>Patel, Zulfikar M</creatorcontrib><creatorcontrib>Patel, Harshil R</creatorcontrib><creatorcontrib>Dhanani, Shreekant S</creatorcontrib><creatorcontrib>Shah, Bhavya H</creatorcontrib><title>DOSE RESPONSE RELATIONSHIP OF HYDROXYCHLOROQUINE SULPHATE IN THE TREATMENT OF RHEUMATOID ARTHRITIS: A RANDOMISED CONTROL STUDY</title><title>International journal of pharmaceutical sciences and research</title><description>Background: RA is an autoimmune disease triggered by faulty immune system and affects various joints of body including wrist and finger. Nowadays slow acting or DMARDs (Disease modifying anti-rheumatoid drugs) are mainstay of treatment in RA. HCQs belong to this group. They are slow acting so they take weeks to months to become effective. HCQ is less effective when compared to gold or penicillamine but its tolerance is better than other DMARDs. Objective: 1. To observe a dose-response relationship for hydroxychloroquine (HCQ), in terms of the proportion of patients achieving the Paulus 20% criteria for improvement in patients with rheumatoid arthritis (RA) receiving a 24 week loading regimen of 400, 800, or 1,200 mg HCQ daily. 2. To investigate possible relationships between increased dosage of HCQ and measures of efficacy and toxicity. Methods: 422 Patients with RA began a 24-week study comparing 3 different doses of HCQ at 400, 800, or 1,200 mg/day, followed by 18 weeks of open-label HCQ treatment at 400 mg/day. Patients were evaluated at 0, 6 and 18 week to measure the efficacy and adverse reaction of the drug. Results: There was a positive correlation between the Paulus 20% improvement criteria response and increased dose of HCQs during weeks 1-6 (P &lt; 0.001). Adverse gastrointestinal events were associated with higher HCQ levels (P &lt;=0.001) during 0-3 weeks. Conclusion: There is a weak, but predictable, relationship between increase HCQs dosage and efficacy of treatment with HCQ.</description><issn>0975-8232</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><recordid>eNo9UMtOwzAAi5CQmMb-IQcO49CS5tGm3KI2kKCuKWkqsdPURyaBBht0u_LtlIfwxZZlWZYBuIpQGBFE0Y1-qGobojRhAccEh3yJr0PO4oDxMzD79y_AYhxf0IQYRxEnM_CZm1pCK-vKlD-iEE5PUukKmjuo1rk1T-tMFcaax0aXEtZNUSnhJNQldEpCZ6VwK1m677xVslkJZ3QOhXXKaqfrWyigFWVuVrqWOcxM6awpYO2afH0JzrftbvSLP56D5k66TAWFudeZKILDNPMYDDilHnFK2yHGybaPhzjiyYBJhyLcJdMD_dBT7FPEeh8lLYsp7wnvGE09H7qOzMHyt_fwsX8_-fG4eX0ee7_btW9-fxo3U1vCCaUsIV9lfVnS</recordid><startdate>20170201</startdate><enddate>20170201</enddate><creator>Modi, Jayprakash V</creator><creator>Patel, Kaushal R</creator><creator>Patel, Zulfikar M</creator><creator>Patel, Harshil R</creator><creator>Dhanani, Shreekant S</creator><creator>Shah, Bhavya H</creator><scope>7QO</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope></search><sort><creationdate>20170201</creationdate><title>DOSE RESPONSE RELATIONSHIP OF HYDROXYCHLOROQUINE SULPHATE IN THE TREATMENT OF RHEUMATOID ARTHRITIS: A RANDOMISED CONTROL STUDY</title><author>Modi, Jayprakash V ; Patel, Kaushal R ; Patel, Zulfikar M ; Patel, Harshil R ; Dhanani, Shreekant S ; Shah, Bhavya H</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p118t-d294e0844ad627fc6d6187d23b012b7040cdc42e905ce17a5648c38b549e8dbb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><toplevel>online_resources</toplevel><creatorcontrib>Modi, Jayprakash V</creatorcontrib><creatorcontrib>Patel, Kaushal R</creatorcontrib><creatorcontrib>Patel, Zulfikar M</creatorcontrib><creatorcontrib>Patel, Harshil R</creatorcontrib><creatorcontrib>Dhanani, Shreekant S</creatorcontrib><creatorcontrib>Shah, Bhavya H</creatorcontrib><collection>Biotechnology Research Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><jtitle>International journal of pharmaceutical sciences and research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Modi, Jayprakash V</au><au>Patel, Kaushal R</au><au>Patel, Zulfikar M</au><au>Patel, Harshil R</au><au>Dhanani, Shreekant S</au><au>Shah, Bhavya H</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>DOSE RESPONSE RELATIONSHIP OF HYDROXYCHLOROQUINE SULPHATE IN THE TREATMENT OF RHEUMATOID ARTHRITIS: A RANDOMISED CONTROL STUDY</atitle><jtitle>International journal of pharmaceutical sciences and research</jtitle><date>2017-02-01</date><risdate>2017</risdate><volume>8</volume><issue>2</issue><spage>856</spage><epage>856</epage><pages>856-856</pages><eissn>0975-8232</eissn><abstract>Background: RA is an autoimmune disease triggered by faulty immune system and affects various joints of body including wrist and finger. Nowadays slow acting or DMARDs (Disease modifying anti-rheumatoid drugs) are mainstay of treatment in RA. HCQs belong to this group. They are slow acting so they take weeks to months to become effective. HCQ is less effective when compared to gold or penicillamine but its tolerance is better than other DMARDs. Objective: 1. To observe a dose-response relationship for hydroxychloroquine (HCQ), in terms of the proportion of patients achieving the Paulus 20% criteria for improvement in patients with rheumatoid arthritis (RA) receiving a 24 week loading regimen of 400, 800, or 1,200 mg HCQ daily. 2. To investigate possible relationships between increased dosage of HCQ and measures of efficacy and toxicity. Methods: 422 Patients with RA began a 24-week study comparing 3 different doses of HCQ at 400, 800, or 1,200 mg/day, followed by 18 weeks of open-label HCQ treatment at 400 mg/day. Patients were evaluated at 0, 6 and 18 week to measure the efficacy and adverse reaction of the drug. Results: There was a positive correlation between the Paulus 20% improvement criteria response and increased dose of HCQs during weeks 1-6 (P &lt; 0.001). Adverse gastrointestinal events were associated with higher HCQ levels (P &lt;=0.001) during 0-3 weeks. Conclusion: There is a weak, but predictable, relationship between increase HCQs dosage and efficacy of treatment with HCQ.</abstract><doi>10.13040/IJPSR.0975-8232.8(2).856-58</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier EISSN: 0975-8232
ispartof International journal of pharmaceutical sciences and research, 2017-02, Vol.8 (2), p.856-856
issn 0975-8232
language eng
recordid cdi_proquest_miscellaneous_1877834457
source EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection
title DOSE RESPONSE RELATIONSHIP OF HYDROXYCHLOROQUINE SULPHATE IN THE TREATMENT OF RHEUMATOID ARTHRITIS: A RANDOMISED CONTROL STUDY
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T06%3A51%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=DOSE%20RESPONSE%20RELATIONSHIP%20OF%20HYDROXYCHLOROQUINE%20SULPHATE%20IN%20THE%20TREATMENT%20OF%20RHEUMATOID%20ARTHRITIS:%20A%20RANDOMISED%20CONTROL%20STUDY&rft.jtitle=International%20journal%20of%20pharmaceutical%20sciences%20and%20research&rft.au=Modi,%20Jayprakash%20V&rft.date=2017-02-01&rft.volume=8&rft.issue=2&rft.spage=856&rft.epage=856&rft.pages=856-856&rft.eissn=0975-8232&rft_id=info:doi/10.13040/IJPSR.0975-8232.8(2).856-58&rft_dat=%3Cproquest%3E1877834457%3C/proquest%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1877834457&rft_id=info:pmid/&rfr_iscdi=true